Pharma Industry News

Disappointing results from CureVac’s COVID-19 vaccine as phase 2/3 study shows only 47% efficacy

Vaccine candidate failed to meet prespecified measure of statistical success in clinical trial

Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]